Fazirsiran Improves Liver Enzyme Concentration in AATD Trial
Fazirsiran is associated with a notable reduction in the concentration of Z-AAT, the most common form of alpha-1 antitrypsin (AAT) causing AAT deficiency (AATD), in the serum and liver as well as with improvements in the concentrations of liver enzymes, according to the results of a phase 2 clinical trial published in the New England…